Immatics Biotechnologies GmbH
50 articles with Immatics Biotechnologies GmbH
8/20/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
6/5/2020Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
Former Head of Oncology Cell Therapy Research Unit at GSK to lead clinical development at Immatics
T cell redirecting cancer company Immatics Biotechnologies entered into a merger agreement with Arya Sciences Acquisition Corp. that will give the Germany-based company a listing on the Nasdaq exchange under the ticker symbol IMTX.
Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies
Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced it has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications.
Immatics is eligible for more than $550 million in various commercial milestone payments for each product as well as additional royalties.
2/20/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
Immatics Implements Genedata Biologics® into Proprietary T-Cell Receptor Discovery and Engineering XCEPTOR® Platform
Leading immuno-oncology company adopts Genedata Biologics® to support the discovery and development of TCRs for adoptive cell therapies and bispecific TCR molecules
The two companies struck a strategic collaboration and option agreement to harness the power of Immatics’ T-Cell Receptor Engineered T-cell Therapy programs and aim them at solid tumors.
Immatics Biotechnologies GmbH announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer.
Study of investigational personalized T-cell therapy IMA101 expanded to explore combination with anti-PDL1 antibody
US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
This is a significant achievement for the Company and demonstrates the breadth of Immatics’ innovation power and the quality of its science.
Immatics Initiates Second Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers
Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA202, its second T-cell receptor (TCR)-transduced adoptive cell therapy program.
Denmark-based Genmab A/S struck a discovery and development deal with Immatics Biotechnologies GmbH.
Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies
Immatics Biotechnologies GmbH, announced today that it has entered into a research collaboration and license agreement with Genmab A/S (Nasdaq Copenhagen: GEN).
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
Thomas joins Immatics from the Merck Group, where he is currently CFO of the Allergopharma Business Unit.
Immatics, a leading company in the field of cancer immunotherapy, announced today that Roche has exercised its option under the existing discovery, development and commercialization agreement between the companies to exclusively license from Immatics a proprietary immunotherapy target for further development and commercialization in oncology.